Skip to main content
Evidence Snapshot

Hepatitis B virus

CHEMBL613497 ORGANISM Hepatitis B virus
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T06:13:21Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL613497
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Hepatitis B virus as ChEMBL target CHEMBL613497. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Hepatitis B virus
ORGANISM · Hepatitis B virus
As of 2026-09-13
ChEMBL target ID
CHEMBL613497
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Hepatitis B virus matters

As of 2026-09-13

Hepatitis B virus is reviewed as Hepatitis B virus; the current evidence base includes 30 approved drugs, 4226 compounds, and 1536 assays, with lead potency reaching pChEMBL 10.2.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 30 approved drugs, 4226 compounds, and 1536 assays for this target. The dominant activity type is IC50. CHEMBL5314362 is the current potency anchor at pChEMBL 10.2.

Use CHEMBL5314362 as the tractability anchor when discussing potency (pChEMBL 10.2).

Activity source · ChEMBL 36 via Core Engine
30 approved pChEMBL 10.2
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Hepatitis B virus matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

4226
Total Compounds
1536
Total Assays
30
Approved Drugs
IC50: 3200.0, EC50: 2768.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL5314362
 10.2 IC50 Approved
No preferred name
CHEMBL483
 10.2 EC50 Clinical
No preferred name
CHEMBL5285547
 10.0 EC50 —
No preferred name
CHEMBL4875146
 9.7 EC50 —
No preferred name
CHEMBL5206918
 9.7 IC50 —

Approved Drugs

Structure Compound First Approval
TENOFOVIR ALAFENAMIDE FUMARATE
CHEMBL2364637
 2015
TENOFOVIR ALAFENAMIDE
CHEMBL2107825
 2015
TELBIVUDINE
CHEMBL374731
 2006
ENTECAVIR
CHEMBL5314362
 2005
ENTECAVIR ANHYDROUS
CHEMBL713
 2005
EMTRICITABINE
CHEMBL885
 2003
NITAZOXANIDE
CHEMBL1401
 2002
ADEFOVIR DIPIVOXIL
CHEMBL922
 2002
TENOFOVIR DISOPROXIL FUMARATE
CHEMBL1486
 2001
TENOFOVIR DISOPROXIL
CHEMBL1538
 2001
PENCICLOVIR
CHEMBL1540
 1996
LAMIVUDINE
CHEMBL141
 1995
CYCLOSPORINE
CHEMBL160
 1983
ACYCLOVIR
CHEMBL184
 1982
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T06:13:21Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL613497